# MDT Completion Checker — REFRESH

Last updated: 2026-07-24 | pipeline: lean-6module-v1.1 | as_of: 2026-07-24 | prior: `../2026-07-05/`

---

## Standard File Set Checklist

| File | Status | Notes |
|---|---|---|
| raw/developments_sweep_2026-07-24.md | DONE | New-developments sweep (price, SPR, MiniMed IPO+litigation, Hugo AI, RDN, PFA, China, analysts) — multi-source cross-checked |
| facts.md | DONE | EVIDENCE (47 items, refreshed) / INTERPRETATION (9) / SENTIMENT (3) / OPEN (8) |
| claim_ledger.csv | DONE | 67 claims, each with source_id, tier, as_of |
| source_register.md | DONE | ~38 sources (11 A1, 3 A2, remainder B1/B2, 1 labeled C2) — well above the ≥6 min |
| business_model.md | DONE | Refresh deltas (MiniMed deconsolidating, AI layer, mix shift) |
| value_chain_map.md | DONE | Refresh deltas (reimbursement layer live, AI compute layer) |
| moat_map.md | DONE | 5 moat sources refreshed (RDN now quantified; Hugo AI; competition offsets) — signal +1 held |
| operator_underwriting.md | DONE | Martha/Piéton 3/5 held; execution on MiniMed + SPR + margin-question partly cleared |
| bottleneck_map.md | DONE | Per-platform bottleneck movement; Hugo adoption-speed still the binding constraint |
| financials/financial_quality.md | DONE | Balance sheet refreshed; margin bifurcation largely explained; MiniMed dilution bounded — +1 held |
| inversion_map.md | DONE | 5 kill paths (litigation + China moved favorably; TAVR/PFA-competition new) — signal 0→+1 |
| valuation.md | DONE | Flat price $83.21; EV/EBITDA ~10.9x; IRRs refreshed; buy-below unchanged — +1 held |
| model/scenario_model.csv | DONE | Bear/base/bull 3yr/5yr; net debt + RDN/MiniMed notes refreshed |
| ic_panel.md | DONE | 5-soul refresh — unanimous STARTER held, no fabricated quotes |
| decision_card.json | DONE | Locked schema; valid JSON; net signal +4/0 → +5/0 |
| decision_card.md | DONE | Human-readable; 3-open-questions table; kill criteria expanded (K-A..K-G) |
| **comparison_vs_2026-07-05.md** | DONE | **Required dedicated file** — side-by-side, module deltas, 3-open-question state, STRENGTHEN verdict |
| freshness.json | DONE | LIVE manifest (price re-verified 2 ways; qualitative fields incl. active_litigation) |
| freshness_check.json / .txt | **PASS** | verify_freshness.py exit 0; 6 tripwires PASS, 1 WARN (guidance 50d — expected/annual) |
| brief-v1.html | DONE | MDT 决策简报 refresh, as_of 2026-07-24 |
| audit.md | DONE | Stale-claim check, internal consistency, discipline compliance |
| research_status.md | DONE | Completeness ~78%; OPEN-item status vs prior |
| completion_checker.md | DONE (this file) | |

---

## Completeness Self-Assessment: ~78% (up from ~65%)

**What improved vs the prior run**:
- Price re-verified two independent ways ($83.21, exact match) — freshness gate PASS
- **Earnings-CALL transcript accessed** — China / Hugo / RDN / PFA now on the record (prior run had only undated commentary)
- **MiniMed S-1 + FY2026 10-K litigation footnote accessed** — the litigation is now QUANTIFIED (15 suits/55 people) and its ISOLATION mechanism (Separation Agreement → SpinCo) is documented
- **Prior OPEN items resolved/improved**: O5 (spinoff) RESOLVED; O4 (margin bifurcation) LARGELY EXPLAINED; O2 (China) improved to on-record
- **New quantified platform** (renal denervation ~$100M) and **cleaner balance sheet** (net debt ~$18.7B) obtained

**What's still explicitly incomplete**:
- **O1 Hugo revenue** — STILL unquantified (the gating gap; likely unresolvable until MDT discloses). Unchanged.
- **O2 hard current-year China %** — improved to on-record qualitative, but the numeric FY2026 figure (10-K geographic footnote) not read verbatim
- **SEC 10-K document-body** — not read verbatim (EDGAR bot-block persists); litigation count obtained via a tracker quoting the 10-K + the metadata API
- **China domestic robotics competitors** (MicroPort MedBot/Toumai, Surgerii) — STILL not researched; flagged for the career thread
- **Clean post-MiniMed RemainCo restated base** — not yet published (guide includes full-year Diabetes)

---

## Verdict

**PASS — refresh meets the standard.** All required files present (incl. the mandatory `comparison_vs_2026-07-05.md`), internally consistent (audit.md), freshness gate PASS. The refresh materially advanced two of the three prior open questions (China, MiniMed litigation) and cleaned up two financial flags (margin bifurcation, balance sheet), while honestly logging that the #1 question (Hugo scale) is unchanged and two new competitive risks (TAVR, PFA entrants) emerged. Next-refresh priorities: (1) Hugo US revenue disclosure (Q1 FY2027, 2026-09-01), (2) 10-K China geographic footnote, (3) MiniMed split-off + litigation-isolation cleanliness, (4) China-robotics-competitor research, (5) PFA share durability vs J&J/BSX.
